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Abstract
Background: Hepatitis virus B (HBV) has infected millions of people worldwide. Notably, such infections can be
associated with hepatic complications. Levels of apolipoprotein M (apoM), a component of high-density lipoprotein
(HDL), are known to be significantly elevated in patients with chronic hepatitis B (CHB). The aim of this study was
to investigate the relationship between HBV DNA load in serum and serum apoM levels in patients with CHB.
Methods: A total of 73 HBeAg-negative CHB patients, 50 HBeAg-positive CHB patients, and 79 non-CHB controls
were included in the study cohort. The age and body mass index (BMI) of the study participants were matched.
Serum levels of apoM and the HBV antigens HBsAg and HBeAg were measured by enzyme-linked immunosorbent
assay (ELISA) analysis. Serum levels of alanine aminotransferase (ALT), aspartate transaminase (AST), cholesterol, and
triglycerides (TG) were assessed using an automatic biochemical analyzer. Serum HBV DNA levels were quantified
by real-time PCR analysis. Data were analyzed by Spearman’s rank correlation coefficient, Pearson correlation
coefficient, and multivariate linear regression model (continuous variables), or Student’s t-test (mean differences).
Results: Both the HBeAg-negative CHB and HBeAg-positive CHB patient groups exhibited elevated serum levels of
apoM. Moreover, serum apoM levels were positively correlated with serum HBV DNA levels in HBeAg-negative CHB
patients (r = 0.394, p < 0.001). Conversely, there was no significant relationship between apoM and HBV DNA levels
in the HBeAg-positive CHB group (r = 0.197, p = 0.170). The median log copies/mL value for HBV DNA (4.00) was
considered the cutoff point for the HBeAg-negative CHB group. Notably, a significant number of patients with HBV
DNA levels above the cutoff point also had higher serum apoM levels (63.38 ± 29.84 vs. 41.41 ± 21.84; p = 0.001).
Conclusions: Our findings reveal that the correlation between serum apoM levels and viral loads may depend on
HBeAg status, as serum apoM levels were positively correlated with HBV DNA levels in HBeAg-negative CHB
patients. These results suggest that HBeAg may play a role in apoM-related lipid metabolism and anti-inflammatory
functions in hepatitis B patients. Thus, our findings may facilitate the clinical management of HBV infection.
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Background
Hepatitis B virus (HBV) infection causes chronic liver
disease in >350 million people worldwide and this dis-
ease is positively correlated with incidences of liver
cirrhosis and hepatocellular carcinoma. Chronic liver
diseases can interfere with hepatic metabolism of lipo-
proteins and apolipoproteins. Moreover, the ongoing
replication of HBV in chronic hepatitis B (CHB) induces
oxidative stress and is associated with inflammation of
the liver [1–3]. Factors that govern viral replication and
determine infection outcome remain unclear, but it is
known that host factors play a major role in these
processes [4].
Apolipoprotein M (apoM) is a 26-kD apolipoprotein
that is primarily associated with high-density lipopro-
teins (HDL); however, a small proportion of this protein
also interacts with triglyceride-rich lipoprotein (TGRLP)
and low-density lipoprotein (LDL) in the serum. apoM is
a member of the lipocalin protein superfamily and is
exclusively expressed in hepatocytes and kidney tubular
cells [5, 6]. This protein plays a variety of biological func-
tions, e.g., anti-oxidative function [7], anti-inflammatory
function [8], promoting pre-β HDL formation [9], and in-
creasing cholesterol efflux from foam cells [10].
Previous studies reported that chronic hepatitis
patients exhibit higher serum apoM levels than healthy
control subjects [11, 12]. Similarly, HepG2 cells
transfected with an infectious HBV clone were found to
express significantly higher levels of apoM mRNA and
protein than uninfected HepG2 cells in vitro. Moreover,
apoM suppressed HBV replication in HepG2 cells [13].
However, the association between apoM expression and
HBV replication rate in CHB patients is poorly under-
stood. Therefore, the aim of the present study was to
investigate the association between apoM and HBV
replication rate to facilitate the management of anti-viral
treatment in clinical practice.
Methods
Subjects
CHB patients were recruited at the Second Xiangya
Hospital (Changsha, Hunan, PR China) between June
2015 and June 2016. From the 200 individuals screened,
73 HBsAg(+) HBeAg(−) CHB patients and 50 HBsAg(+)
HBeAg(+) CHB patients were enrolled in this study. The
mean age of the patients in the HBsAg(+) HBeAg(−)
group was 44 ± 13 years, and the group was comprised
of 62 males and 11 females. Meanwhile, the mean age of
the patients in the HBsAg(+) HBeAg(+) group was 40 ±
12 years, and the group was comprised of 43 males and
7 females (Table 1). CHB was diagnosed based on serum
HBsAg positivity for at least 6 months. The exclusion
criteria for CHB were as follows: (1) positive for hepatitis
C virus, hepatitis D virus, and human immunodeficiency
Table 1 Clinical and biochemical characteristics of the patients included in this study
Control HBeAg-negative HBeAg-positive
Subjects, n 79 73 50
Demographics
Age, years 44 ± 12 44 ± 13 40 ± 12
Sex, % male 87% 85% 86%
Body mass index, kg/m2 22.2 ± 2.2 22.3 ± 2.1 22.1 ± 2.1
Lipids profile
Triglycerides, mmol/L 1.1 ± 0.41 1.72 ± 0.50* 2.74 ± 0.62#&
Total cholesterol, mmol/L 4.4 ± 0.57 3.35 ± 1.33* 4.12 ± 1.21&
HDL-C, mmol/L 1.35 ± 0.21 0.67 ± 0.47* 0.60 ± 0.36#
LDL-C, mmol/L 2.86 ± 0.53 1.96 ± 0.89* 2.59 ± 1.10&
Apolipoprotein A, g/L 1.38 ± 0.19 0.67 ± 0.39* 0.62 ± 0.34#
Apolipoprotein B, g/L 0.97 ± 0.16 0.99 ± 0.44 1.24 ± 0.34#&
Apolipoprotein M, mg/L 13.95 ± 7.11 52.42 ± 28.09* 58.32 ± 27.06#
Lipoprotein(a), g/L 102 ± 2.81 20.67 ± 3.21* 26.72 ± 3.73#
liver biochemical profile
Alanine aminotransferase, IU/L 18.25 ± 1.56 99.73 ± 4.50* 216.77 ± 4.17#&
Aspartate transaminase, IU/L 20.11 ± 1.25 99.74 ± 2.95* 171.25 ± 2.80#&
Log HBV DNA 4.32 ± 2.03 5.61 ± 1.97&
Data are presented as means ± standard deviations. Values for triglyceride, lipoprotein a, ALT, and AST levels were converted into a logarithmic form prior to
analysis. *p < 0.05, HBeAg-negative chronic hepatitis B (CHB) compared to the control. #p < 0.05, HBeAg-positive CHB compared to the control. &p < 0.05,
HBeAg-positive CHB compared to HBeAg-negative CHB
HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, IU international units
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virus antibodies; (2) cirrhosis and hepatocellular carcin-
oma; (3) autoimmune hepatitis and alcoholic liver
disease; (4) diabetes; (5) immunological disease; (6)
cancer; (7) renal disease; (8) heart disease; and (9) anti-
viral therapy treatment. Lastly, the control group was
comprised of 79 age- and sex-matched HBsAg(−) volun-
teers who underwent physical examination in our
hospital. All subjects provided signed Informed Consent
Forms and the study protocol was approved by the
Second Xiangya Hospital Investigational Review Board.
Blood sampling
Following overnight fasting (12 h) and at least 20 min of
rest, blood samples were collected from each subject.
After centrifugation at 1200 × g for 5 min, sera were col-
lected, aliquoted, and stored at −80 °C until use.
Enzyme-linked immunosorbent assay (ELISA) for apoM
determinations
Serum apoM levels were measured by sandwich ELISA
(Yuan Tai Bio Inc., Changsha, Hunan, People’s Republic
of China) analysis. Absorbance was measured at 450 nm,
with a background reading at 620 nm, using an ELX-800
absorbance reader (BioTek Instruments, Inc., Winooski,
VT, USA). The concentration of apoM in each sample
were determined using a standard curve.
Virological assessment
Serum levels of HBsAg and HBeAg were measured via
ELISA analysis using HBV S antigen and HBV E antigen
diagnostic kits (Ke Hua Bio Inc., Shanghai, PR China),
respectively. HBV DNA was extracted from 200 μL
aliquots of serum using a Hepatitis B Viral DNA Quanti-
tative Fluorescence Diagnostic Kit (Sheng Xiang Bio
Inc., Changsha, Hunan, PR China), and quantified by
real-time polymerase chain reaction (PCR) using an ABI
7000 real-time detection system (Applied Biosystems,
Foster City, CA, USA).
Lipoprotein and liver biochemical assays
Levels of serum triglyceride (TG), total cholesterol
(THOL), HDL cholesterol (HDL-C), LDL cholesterol
(LDL-C), apolipoprotein A (apoA), apolipoprotein B
(apoB), lipoprotein a (Lpa), alanine aminotransferase
(ALT), aspartate transaminase (AST), and total bile acid
(TBA) were determined using an ARCHITECTc8000
System (Abbott Laboratories, Irving, TX, USA).
Statistical analyses
Continuous data are expressed as means ± standard de-
viations. Relationships between continuous variables
were tested by Spearman’s rank correlation coefficient,
Pearson correlation coefficient, and multivariate linear
regression model analyses. Mean differences were com-
pared by Student’s t-test. Statistical analyses were per-
formed using SPSS 20.0 (SPSS Statistics, Inc., Chicago,
IL, USA) or GraphPad Prism 5.0 (GraphPad Software,
La Jolla, CA, USA) software. Two-tailed p-values < 0.05
were considered statistically significant.
Results
Demographic and clinical characteristics of the study
subjects
Of the 200 CHB patients screened for participation in
this study, 73 HBeAg-negative and 50 HBeAg-positive
CHB patients were identified and assessed according to
the criteria delineated in the Methods section. Addition-
ally, of the 100 control subjects screened for participa-
tion, 11 failed the eligibility criteria and 10 refused to
participate. As such, 79 control subjects were evaluated
in this study (Fig. 1). The demographic and biochemical
characteristics of the subjects are summarized in Table 1.
Notably, there were no differences between the control,
HBeAg-negative, and HBeAg-positive CHB groups in
regard to age (44 ± 12, 44 ± 13, and 40 ± 12), gender (87,
85, and 86% male), and BMI (22.2 ± 2.2, 22.3 ± 2.1, and
22.1 ± 2.1), respectively. Conversely, the patients in the
HBeAg-negative and HBeAg-positive groups exhibited
Fig. 1 flowchart of the study
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significantly higher (p < 0.05) mean serum apoM levels
(52.42 ± 28.09 and 58.32 ± 27.06 mg/L, respectively) than
those in the control group (13.95 ± 7.11 mg/L). Mean-
while, there was no significant difference between the
HBeAg-negative and HBeAg-positive groups in average
apoM serum levels or HBV DNA levels (4.28 ± 2.07 and
5.61 ± 1.97 log copies/mL, respectively).
Serum liver biochemical profiles of HBeAg-negative CHB
patients, HBeAg-positive CHB patients, and normal
subjects
As shown in Fig. 2, the average serum ALT and AST
levels of the HBeAg-negative CHB patients were 99.73 ±
4.50 IU/L and 99.74 ± 2.95 IU/L, respectively, which
were significantly higher than those of the normal
subjects (18.25 ± 1.56 IU/L and 20.11 ± 1.25 IU/L,
respectively; p < 0.01). Notably, however, the ALT and
AST levels of the patients in the HBeAg-positive group
(216.77 ± 4.17 IU/L and 171.25 ± 2.8 IU/L; p < 0.01) were
even higher than those observed in the HBeAg-negative
group.
Routine serum lipid levels in HBeAg-negative CHB patients,
HBeAg-positive CHB patients, and normal subjects
HBeAg-positive CHB patients exhibited significantly
higher (p < 0.01 for each) serum Trig levels (2.74 ±
0.62 mmol/L) than those in the HBeAg-negative (1.72 ±
0.50 mmol/L) and control (1.1 ± 0.41 mmol/L) groups
(Fig. 3). Moreover, the serum Trig levels of the HBeAg-
negative group were also significantly higher than those
of the control (p < 0.01). Meanwhile, serum HDL-C
levels were higher in both the HBeAg-negative and
HBeAg-positive CHB patients than in control subjects;
however, there was no difference in serum HDL-C levels
between the HBeAg-negative and HBeAg-positive CHB
groups. Likewise, there were no differences in THOL
and LDL-C levels between the HBeAg-positive CHB
patients and control subjects. Conversely, the HBeAg-
negative CHB patients exhibited elevated levels of
THOL and LDL-C, compared to those in the other two
groups (Fig. 3).
Serum apolipoprotein levels in HBeAg-negative CHB patients,
HBeAg-positive CHB patients, and normal subjects
While serum apoM levels were higher in both the
HBeAg-negative and HBeAg-positive CHB patients than
control subjects, these patients exhibited lower serum
levels of apoA and Lpa than the controls (Fig. 4). In
addition, there were no differences in apoA and Lpa
levels between the two CHB groups. Conversely,
HBeAg-positive patients exhibited higher serum apoB
levels than both the HBeAg-negative patients and
control subjects.
Serum apoM and HBV DNA load in HBeAg-negative and
HBeAg-positive CHB patients
As summarized in Table 2, there was no significant
difference in the serum levels of apoM between the
HBeAg-negative and HBeAg-positive groups (52.42 ±
28.09 vs. 58.32 ± 27.06 mg/L; p = 0.248); however, the
HBeAg-positive CHB patients exhibited significantly
higher HBV DNA loads than those in the HBeAg-negative
group (4.28 ± 2.07 vs. 5.61 ± 1.97 log copies/mL; p < 0.01).
Correlation analysis of serum apoM and HBV DNA levels
in HBeAg-negative and HBeAg-positive CHB patients
Notably, we detected a positive association between serum






























Fig. 2 Serum liver biochemical profiles of chronic hepatitis B (CHB)
patients. Serum concentrations of liver biochemical markers in CHB
patients, grouped according to HBeAg status, and healthy control
subjects. *p < 0.05, **p < 0.01, compared to the control group. #p <



















































Fig. 3 Chronic hepatitis B (CHB) patients exhibit elevated serum
triglyceride levels and decreased serum levels of total cholesterol
(THOL), high-density lipoprotein cholesterol (HDL-C), and low-density
lipoprotein cholesterol (LDL-C). Serum concentrations of THOL, HDL-C,
and LDL-C in CHB patients, grouped according to HBeAg status, and
healthy control subjects. *p < 0.05, **p < 0.01, compared to the control
subjects. #p < 0.05, between the two groups indicated by the
horizontal line
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CHB group (r = 0.394; p < 0.01), but not in the HBeAg-
positive CHB patients group (r = 0.197; p = 0.170) (Fig. 5).
Association between serum apoM and HBV DNA levels in
HBeAg-negative CHB patients
Using the median value of 4.28 log copies/mL HBV
DNA as a cutoff point, we observed that patients with
HBV DNA levels exceeding that value also showed
elevated levels of apoM (63.38 ± 29.84 vs. 41.41 ± 21.84 mg/
L; p = 0.001), ALT (213.8 ± 3.4 vs. 45.3 ± 3.9 IU/L; p < 0.001)
and AST (179.8 ± 2.6 vs. 54.6 ± 2.4 IU/L; p < 0.001), respect-
ively (Table 3). Moreover, multivariate regression analysis,
using log HBV DNA as a continuous dependent variable
and apoM, HDL-C, LDL-C, CHOL, TG, apoA, apoB, age,
sex, BMI, AST, ALT, and TBA as independent variables,
detected a statistically significant positive association
between log HBV DNA levels and serum apoM levels
(p < 0.001; β = 0.029) (Table 4).
Discussion
In this study, we measured the serum levels of apoM
and lipids in HBeAg-negative CHB, HBeAg-positive
CHB, and control subjects, and screened for associations
between serum apoM levels and HBV DNA load.
Indeed, the key finding of our study was a significant
positive correlation in vivo between serum apoM and
HBV DNA levels in HBeAg-negative patients. These
results are consistent with and extend previous findings
that CHB patients exhibit elevated serum apoM levels
[11, 12].
In this study, CHB patients exhibited lower serum
levels of HDL-C and apoA than the control subjects. In
contrast, these patients also presented with higher serum
levels of apoM, which primarily interacts with HDL-C,
than the controls. Elevated apoM levels were also
reported in cases of chronic inflammatory disease and
decreased in acute inflammatory disease [14, 15]. The
potential mechanisms underlying the anti-inflammatory
activities and immune-modulatory properties of apoM
have been previously characterized [16–18], and apoM is
known to be widely distributed within the pool of serum
lipoproteins under inflammatory conditions [19, 20]. In
chronic inflammatory disease, apoM functions as an
innate protective factor that is up-regulated to resist in-











































Fig. 4 Chronic hepatitis B (CHB) patients exhibit elevated serum
apoM and apoB levels and decreased serum apoA and lipoprotein a
(Lpa) levels. Serum concentrations of apolipoproteins in CHB
patients, grouped according to HBeAg status, and healthy control
subjects. *p < 0.05, **p < 0.01, compared to the control group. #p <
0.05, between two groups indicated by the horizontal line
Table 2 Serum apoM levels and hepatitis B virus (HBV) DNA
loads in HBeAg-negative and HBeAg-positive chronic hepatitis B
(CHB) patients
HBeAg-negative HBeAg-positive p-value
Apolipoprotein M, mg/L 52.42 ± 28.09 58.32 ± 27.06 0.248
LogHBV DNA 4.32 ± 2.03 5.61 ± 1.97 0.001
Data are means ± standard deviations. The p-values refer to comparisons
between the HBeAg-negative and HBeAg-positive groups
pearson's rho=0.394,p<0.001





















Fig. 5 Correlation between serum levels of apoM levels hepatitis B
(HBV) DNA. There was a positive correlation between the log10 HBV
DNA value and serum apoM levels in (a) HBeAg-negative CHB
patients (r = 0.394; p < 0.01), but not in (b) HBeAg-positive CHB
patients (r = 0.197; p = 0.170)
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showed that apoM could limits endothelial and vascular
inflammation though sphingosine 1-phosphate-
sphingosine 1-phosphate receptor 1 pathway (S1P-SIP1)
[21, 22]. Furthermore, Wang et al. [18] showed that
apoM contributed to the maintenance of CD4+ T
lymphocytes or benefited for modifying T lymphocyte
subgroups in murine spleen. Indeed, apoM-sphingosine
1-phosphate (apoM-S1P) was shown to contribute to in-
nate and adaptive immunity by directly interacting with
bone marrow lymphocyte progenitors and inhibiting
their proliferation via activation of the S1P1/ERK path-
way [17]. We proposed that apoM-S1P may play a role
in resisting chronic inflammation in CHB patients.
What’s more, it may be used as a potential helpful agent
in CHB patients.
The pronounced replication of HBV during CHB has
been linked to the development of cirrhosis and hepato-
cellular carcinoma [23, 24]. Notably, this replication also
seems to be affected by host factors. Previous studies
showed that HBV enhances apoM mRNA and protein
expression, and that elevated levels of apoM suppress
HBV protein expression and viral replication in HepG2
cells. However, these studies found no correlation
between HBV viral load and apoM levels in patients with
CHB [13]. Conversely, in this study, we found that
higher HBV DNA levels were associated with higher
serum apoM concentrations in patients with HBeAg-
negative, but not HBeAg-positive, CHB. Moreover, while
HBV DNA loads were also higher in HBeAg-positive
CHB than in the control subjects, there was no signifi-
cant difference in serum apoM levels between the
HBeAg-positive and HBeAg-negative CHB patients. It is
therefore conceivable that high HBeAg titers have an
inhibitory effect on the HBV DNA-mediated enhancement
Table 3 Association of clinical findings of chronic hepatitis B with HBV DNA levels
HBV DNA <median* HBV DNA >median* p-value
Subjects, n 36 37
Demographics
Age, years 47 ± 12 42 ± 12 0.109
Sex, % male 84 86 0.364
Body mass index, kg/m2 22.2 ± 2.0 22.4 ± 2.4 0.487
Lipid profile
Triglycerides, mmol/L 1.68 ± 0.51 1.77 ± 0.52 0.817
Total cholesterol, mmol/L 3.51 ± 1.31 3.19 ± 1.34 0.308
HDL-C, mmol/L 0.76 ± 0.48 0.58 ± 0.44 0.099
LDL-C, mmol/L 2.07 ± 0.97 1.86 ± 0.82 0.326
Apolipoprotein A, g/L 0.74 ± 0.37 0.61 ± 0.41 0.177
Apolipoprotein B, g/L 0.93 ± 0.45 1.05 ± 0.43 0.241
Apolipoprotein M, mg/L 41.41 ± 21.84 63.38 ± 29.84 0.001
Lipoprotein(a), g/L 30.27 ± 2.64 14.32 ± 3.41 0.005
Liver biochemistry profile
Alanine aminotransferase, IU/L 45.3 ± 3.9 213.8 ± 3.4 <0.001
Aspartate transaminase, IU/L 54.6 ± 2.4 179.8 ± 2.6 <0.001
HBV DNA levels were categorized as higher or lower than the median log copies/mL (4.23 log copies/mL). Values for triglycerides, lipoprotein (a), alanine
aminotransferase, and aspartate transaminase were converted into logarithmic form before analysis. p < 0.05 was considered statistically significant
HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, IU international units
Table 4 Multivariate regression analysis
Beta Standardized Beta p-value
Factor correlation
with Log HBV DNA
apoM 0.029 0.397 <0.001
apoA 0.011 0.002 0.996
apoB 0.085 0.018 0.969
HDL-C −0.268 −0.151 0.881
LDL-C 0.966 0.416 0.181
TG 0.485 0.296 0.382
THOL −0.824 −0.528 0.053
Age −0.001 −0.004 0.976
Sex −1.033 −0.192 0.056
BMI 0.001 0.003 0.967
ALT 0.01 0.149 0.285
AST 0.02 0.22 0.169
TBA −0.001 −0.041 0.775
apoM apolipoprotein M, apoA apolipoprotein A, apoB apolipoprotein B, HDL-C
high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol,
TG triglycerides, THOL total cholesterol, BMI body mass index, ALT alanine
aminotransferase, AST aspartate transaminase, TBA total bile acid. p < 0.05 was
considered statistically significant
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of apoM expression. Liver is a major organ for the synthesis
of lipoproteins and metabolism of lipids. HBV infection dis-
turbs the synthesis of almost all lipoproteins and enzymes
envolving in lipid metabolism [25, 26]. It was reported that
HBV down-regulated the expression of apoA through
affecting ApoA1 promoter activities [27], probably via
promotor hypermethylation [28]. Consistent with these
findings, our results found that apoA was lower in CHB
patients. Previous study showed that serum leptin was
elevated in patients with hepatitis B patients [29], and
apoM expression was lower in leptin deficient ob/ob mice.
After leptin administration, apoM expression was elevated
in the liver and kidney of ob/ob mice [30]. We proposed
that HBV may increase apoM level through enhancing
leptin expression. Several studies have also reported that
HBx promote the expression of LXR [31, 32], and that the
LXR agonist TO901317 enhances the expression of apoM
in Caco-2 cells [33, 34]. Therefore, HBV may mediate the
upregulation of apoM via the RXR/LXR pathway. However,
the molecular mechanism underlying these phenomena
was not analyzed in the present study. As such, future stud-
ies are needed to elucidate the molecular effects of HBeAg
on apoM expression.
There are several limitations to our present study.
First, the number of patients with CHB evaluated herein
was relatively small. Further studies with a larger patient
cohort are therefore needed to confirm our findings.
Another limitation was the imbalanced sex ratio of the
cohort; evaluation of an approximately equal number of
male and female subjects would provide more conclusive
results. Finally, because we did not characterize the HBV
genotypes of the infected patients, it is not clear whether
the correlation between HBV DNA and apoM levels is
dependent on HBV sub-genotypes. Such data would help
determine whether apoM could be utilized as a serum
marker to facilitate the management of CHB in clinical
practice or a potential helpful agent in CHB treatments.
Conclusions
In summary, we detected a correlation between serum
apoM levels and viral loads that may depend on HBeAg
status. Specifically, we detected a positive correlation
between serum apoM and serum HBV DNA levels in
HBeAg-negative, but not HBeAg-positive, CHB patients.
To enhance the reliability of our results, we adjusted for
age, sex, BMI, ALT, AST, TBA, HDL-C, LDL-C, CHOL,
TG, apoA, apoB, and LPa when screening for a correl-
ation between apoM and HBV DNA levels. Our results
support an association between apoM levels and HBV
replication in HBeAg-negative CHB. Since apoM func-
tions as an anti-inflammatory and immune-modulatory
factor, these results suggest that HBeAg may play a role
in apoM-related lipid metabolism and anti-inflammatory
functions in hepatitis B patients. Thus, our findings may
facilitate the clinical management of HBV infection.
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